Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.

Böhm, Steffen; Le, Nhu; Lockley, Michelle; Brockbank, Elly; Faruqi, Asma; Said, Ian; Jeyarajah, Arjun; Wuntakal, Rekha; Gilks, Blake; Singh, Naveena

Böhm, Steffen; Le, Nhu; Lockley, Michelle; Brockbank, Elly; Faruqi, Asma; Said, Ian; Jeyarajah, Arjun; Wuntakal, Rekha; Gilks, Blake; Singh, Naveena.

Afiliação

Böhm S; Department of Medical Oncology, Barts Health NHS Trust, London, UK bohm.st@hotmail.com.
Le N; Cancer Epidemiology and Prevention, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Lockley M; Barts Cancer Institute, Queen Mary University of London, London, UK.
Brockbank E; Department of Gynaecologial Oncology, Barts Health NHS Trust, London, UK.
Faruqi A; Department of Pathology, Barts Health NHS Trust, London, UK.
Said I; Department of Pathology, Barts Health NHS Trust, London, UK.
Jeyarajah A; Department of Histopathology, Mater Dei Hospital, Msida, Malta.
Wuntakal R; Department of Gynaecologial Oncology, Barts Health NHS Trust, London, UK.
Gilks B; Department of Gynaecological Oncology, Queens Hospital, Romford, UK.
Singh N; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.